4.176
전일 마감가:
$4.13
열려 있는:
$4.12
하루 거래량:
8,723
Relative Volume:
0.04
시가총액:
$246.96M
수익:
$33.48M
순이익/손실:
$-52.70M
주가수익비율:
-3.24
EPS:
-1.2889
순현금흐름:
$-49.45M
1주 성능:
-1.51%
1개월 성능:
-0.57%
6개월 성능:
+30.91%
1년 성능:
+40.13%
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
명칭
Orchestra Biomed Holdings Inc
전화
646-343-9298
주소
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
OBIO
Orchestra Biomed Holdings Inc
|
4.22 | 241.69M | 33.48M | -52.70M | -49.45M | -1.2889 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.94 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.74 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
800.08 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.32 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
309.83 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 개시 | TD Cowen | Buy |
| 2025-08-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-03-20 | 개시 | BTIG Research | Buy |
| 2025-01-02 | 개시 | Barclays | Overweight |
| 2024-08-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-25 | 개시 | B. Riley Securities | Buy |
| 2024-01-19 | 개시 | Jefferies | Buy |
| 2023-02-24 | 개시 | Piper Sandler | Overweight |
| 2023-02-07 | 개시 | Chardan Capital Markets | Buy |
모두보기
Orchestra Biomed Holdings Inc 주식(OBIO)의 최신 뉴스
Orchestra BioMed Holdings (OBIO) price target decreased by 11.17% to 11.39 - MSN
OBIO Options Volatility — NASDAQ:OBIO - TradingView — Track All Markets
OBIO Options Chain — NASDAQ:OBIO - TradingView — Track All Markets
How sensitive is Orchestra BioMed Holdings Inc to inflation2026 Market Outlook & Verified High Yield Trade Plans - baoquankhu1.vn
If You Invested $1,000 in Orchestra BioMed Holdings Inc (OBIO) - Stock Titan
Orchestra BioMed : April 2026 Corporate Presentation - marketscreener.com
Orchestra Biomed Holdings Inc (NASDAQ:OBIO) Fits the Minervini High-Growth Momentum Template - ChartMill
Aug Fed Impact: What is Orchestra BioMed Holdings Incs 5 year growth outlook - baoquankhu1.vn
Activity Recap: Does Orchestra BioMed Holdings Inc outperform in volatile markets2026 Market WrapUp & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Analyst Upgrade: How much upside does Orchestra BioMed Holdings Inc have2026 Chart Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
Orchestra BioMed reports 2025 results, advances pivotal clinical trials - MSN
Orchestra BioMed (NASDAQ: OBIO) insider reports RSU tax withholding event - Stock Titan
Orchestra BioMed (OBIO) officer has shares withheld for RSU tax payment - Stock Titan
Orchestra BioMed (OBIO) insider withholds 32,438 RSU shares for tax - Stock Titan
Stock Report: Does Orchestra BioMed Holdings Inc outperform in volatile markets2026 Opening Moves & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Jefferies cuts Orchestra BioMed stock price target on financing costs By Investing.com - Investing.com Australia
Orchestra BioMed (OBIO) to Release Earnings on Wednesday - MarketBeat
Trend Report: How do insiders feel about Orchestra BioMed Holdings IncRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates - MSN
Analysts’ Top Healthcare Picks: Orchestra BioMed Holdings (OBIO), Cardinal Health (CAH) - The Globe and Mail
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Highlights: Will Orchestra BioMed Holdings Inc benefit from geopolitical trends2026 Trends & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
HC Wainwright Has Optimistic Outlook of OBIO Q1 Earnings - MarketBeat
Orchestra BioMed Reports 2025 Results, Advances Pivotal Clinical Trials - MyChesCo
Top Executive Makes Bold Insider Move at Orchestra BioMed - TipRanks
Orchestra BioMed (NASDAQ:OBIO) Insider Purchases 10,000 Shares - MarketBeat
Orchestra BioMed (OBIO) director David Hochman buys 10,000 shares - Stock Titan
Orchestra BioMed (OBIO) First Profitable Quarter Tests Bearish Unprofitability Narrative - simplywall.st
Orchestra BioMed (NASDAQ:OBIO) Raised to Hold at Wall Street Zen - MarketBeat
Orchestra BioMed Holdings (OBIO) Receives a Buy from Chardan Capital - The Globe and Mail
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update - Sahm
Orchestra BioMed Holdings, Inc. (OBIO) surpasses Q4 earnings and revenue estimates - MSN
Orchestra BioMed (NASDAQ:OBIO) Receives "Buy" Rating from Chardan Capital - MarketBeat
Chardan reiterates Orchestra BioMed stock rating on trial focus By Investing.com - Investing.com Canada
Chardan reiterates Orchestra BioMed stock rating on trial focus - Investing.com
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Orchestra BioMed Holdings, Inc. (OBIO) Exceeds Expectations for Q4 Earnings and Revenue - Bitget
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
OBIO: Revenue up 1,539% to $33.5M; strong cash, pivotal trials advancing, more proceeds expected - TradingView
Orchestra BioMed Reports $106.5 Million Cash Position and Major Financial Milestones for 2025 - Quiver Quantitative
Orchestra BioMed Holdings 10-K Summary — Revenue: $— | EPS: $— - TradingView
Orchestra Biomed Holdings Inc (OBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):